**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 65459

**Manuscript Type:** MINIREVIEWS

**COVID-19 and liver dysfunction: What nutritionists need to know**

Wang MK *et al*. COVID-19-related liver dysfunction in nutritional decision

Ming-Ke Wang, Xue-Lu Yu, Li-Yun Zhou, Hong-Mei Si, Ju-Fen Hui, Deng-Yong Hou, Wei-Peng Li, Ji-Shun Yang

**Ming-Ke Wang, Xue-Lu Yu, Li-Yun Zhou, Hong-Mei Si, Ju-Fen Hui, Deng-Yong Hou, Wei-Peng Li,** Department of Disease Control and Prevention, Naval Medical Center of PLA, Naval Medical University, Shanghai 200052, China

**Ji-Shun Yang,** Medical Care Center, Naval Medical Center of PLA, Naval Medical University, Shanghai 200052, China

**Author contributions:** Wang MK wrote the draft; Yu XL, Zhou LY, Si HM, Hui JF, Hou DY, and Li WP collected the literature; Wang MK and Yang JS conceptualized the article and revised the manuscript; and all authors have read and approved the final manuscript.

**Supported by** Major Construction Program of Military Key Disciplines during the 13th Five-Year Plan Period, No. 2020SZ21-15.

**Corresponding author: Ji-Shun Yang, MD, PhD, Director,** Medical Care Center, Naval Medical Center of PLA, Naval Medical University, No. 338 Huaihai West Road, Shanghai 200052, China. jasunyang@foxmail.com

**Received:** March 12, 2021

**Revised:** April 24, 2021

**Accepted: March 27, 2022**

**Published online:**

**Abstract**

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 has brought serious challenges for the medical field. Patients with COVID-19 usually have respiratory symptoms. However, liver dysfunction is not an uncommon presentation. Additionally, the degree of liver dysfunction is associated with the severity and prognosis of COVID-19. Prevention, diagnosis, and treatment of malnutrition should be routinely recommended in the management of patients with COVID-19, especially in those with liver dysfunction. Recently, a large number of studies have reported that nutrition therapy measures, including natural dietary supplements, vitamins, minerals and trace elements, and probiotics, might have potential hepatoprotective effects against COVID-19-related liver dysfunction *via* their antioxidant, antiviral, anti-inflammatory, and positive immunomodulatory effects. This review mainly focuses on the possible relationship between COVID-19 and liver dysfunction, nutritional and metabolic characteristics, nutritional status assessment, and nutrition therapy to provide a reference for the nutritionists while making evidence-based nutritional decisions during the COVID-19 pandemic.

**Key Words:** COVID-19; SARS-CoV-2; Liver dysfunction; Nutritional status assessment; Nutrition therapy

Wang MK, Yu XL, Zhou LY, Si HM, Hui JF, Hou DY, Li WP, Yang JS. COVID-19 and liver dysfunction: What nutritionists need to know. *World J Gastroenterol* 2022; In press

**Core Tip:** Patients with coronavirus disease 2019 (COVID-19) usually have respiratory symptoms, but liver dysfunction is not an uncommon presentation. The degree of liver dysfunction is associated with COVID-19 severity and prognosis. Nutrition has played a critical therapeutic and prognostic role in the management of patients with COVID-19-related liver dysfunction. This review mainly focuses on the possible relationship between COVID-19 and liver dysfunction, nutritional and metabolic characteristics, nutritional status assessment, and nutrition therapy in patients with COVID-19 to provide a reference for the nutritionists while making evidence-based nutritional decisions in the era of COVID-19.

**INTRODUCTION**

Since December 2019, novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been a major global health-related issue and has caused an unprecedented pandemic[1,2]. As of January 2, 2022, a total of 288867634 confirmed cases of COVID-19 and 5437636 deaths have been reported worldwide[3]. The liver is one of the main organs involved in nutrient metabolism, including protein synthesis, glycogen storage, and detoxification[4]. Studies have shown that angiotensin-converting enzyme 2 (ACE2), a functional receptor that allows the entry of SARS-CoV-2 into host cells, is expressed in cholangiocytes (59.7% of cells) and hepatocytes (2.6% of cells), indicating that COVID-19-related liver dysfunction may occur through direct cytotoxicity due to continuous viral replication within liver cells[5-8]. Additionally, COVID-19-related liver dysfunction was observed in approximately 20%-30% of the infected patients, especially in critically ill patients, and it was associated with poor outcomes[9-12]. Therefore, COVID-19-related liver dysfunction should not be ignored.

Meanwhile, almost all patients with liver disease, especially those at an advanced stage, have signs of malnutrition, including mineral and vitamin deficiency[13]. Micronutrient deficiencies may lead to impaired immune responses, including improper cytokine secretion, secretory antibody alterations, and antibody affinity, which increase the susceptibility to SARS-CoV-2 infection[14]. The malnutritional status of the host can also be a virulence factor for SARS-CoV-2 infection[15]. In addition, the nutritional status of COVID-19 patients with liver dysfunction is significantly related to the disease severity. An evaluation of the patient’s nutritional status should not be ignored owing to the implications of nutritional status on the susceptibility, course, severity, and responsiveness to therapies[16,17]. Tailored nutritional therapy prescribed after evaluating the nutritional status has also been an integral part of the comprehensive treatment for patients with COVID-19. This paper mainly focuses on a possible relationship between COVID-19 and liver dysfunction, nutritional and metabolic characteristics, nutritional status assessment, and nutrition therapy in patients with COVID-19.

**COVID-19 AND LIVER DYSFUNCTION**

Liver dysfunction has been reported in a significant proportion of COVID-19 patients, especially in those with a severe illness[5]. Additionally, 2%-11% of patients with COVID-19 suffer from chronic liver disease. The prevalence of liver dysfunction in COVID-19 ranged from 3.75% to 59.04%; most studies reported a prevalence of 20%-30%[9-12]. A cross-sectional study reported that the prevalence of liver dysfunction in patients with COVID-19 was 59.04%; of the 62 patients, 44 (70.9%) were male and 18 (29.03%) were female. The average hospital stay of patients with liver dysfunction was 15 d (range, 10-16 d) compared with 10 d (range, 7-11 d) for patients with normal liver function[12]. In general, patients with COVID-19 who develop liver dysfunction are mostly male, elderly, and obese[5]. Another retrospective cohort study reported that of the 2273 COVID-19 patients at three hospitals in the NewYork-Presbyterian network, 45% suffered from mild liver injury, 21% from moderate liver injury, and 6.4% from severe liver injury. Patients with severe liver dysfunction had elevated levels of inflammatory markers, including ferritin and interleukin-6. They also suffered a worse clinical course, including higher rates of intensive care unit (ICU) admission (69%), intubation (65%), renal replacement therapy (33%), and mortality (42%)[10]. Several studies reported that the presence of liver dysfunction was closely related to higher admission, as well as higher ICU admission and/or death. The measurement of liver biochemical indexes might help the clinicians to evaluate the severity and prognosis of patients with COVID-19[18-23]. The mechanisms of COVID-19-related liver dysfunction may include direct viral cytopathic impairment, secondary liver injury resulting from a systemic inflammatory response or hypoxia-reperfusion, stress-induced liver injury, drug-induced liver damage, and, finally, exacerbation of the pre-existing liver diseases (Figure 1)[5,24-27]. Although COVID-19-related liver injuries are often transient and reversible, physicians, dietitians, and nutritionists need to take notice of the pre-existing liver damage, monitor liver function, improve supportive treatment, and prevent the occurrence of drug-induced liver injury[28].

**NUTRITIONAL AND METABOLIC CHARACTERISTICS OF PATIENTS WITH COVID-19**

The main manifestation of patients with COVID-19 is high fever (range, 37.5-39.0 °C), which induces a catabolic state, including impaired glucose utilization, and increased energy utilization and protein breakdown. The metabolic effect of the temperature increase is said to be 10%-13% for every 1 °C increase, which should be considered in the nutritional recommendations[29]. Additionally, great influence on appetite and consciousness, and direct gastrointestinal damage may lead to nausea, vomiting, diarrhea, and feeding intolerance, which may adversely affect the nutrient intake and nutritional status[29]. Rouget *et al*[30] reported a high prevalence of malnutrition (37.5%) with 26% severe malnutrition according to the Global Leadership Initiative on Malnutrition (GLIM) criteria in a general cohort of patients with COVID-19. Bedock *et al*[31] reported that the overall incidence of malnutrition in COVID-19 patients was 42.1% (moderate: 23.7%; severe: 18.4%), while the incidence of malnutrition in patients admitted to the ICU reached 66.7% using the GLIM criteria. They found that lower albumin levels were related to a higher risk of admission to the ICU, and this association was independent of age and C-reactive protein levels. Li *et al*[32] found a high incidence (52.7%) of malnutrition according to the Mini Nutritional Assessment (MNA) in 182 elderly patients with COVID-19. Additionally, further regression analysis indicated that diabetes, low calf circumference, and low albumin level were independent risk factors for malnutrition. Malnutrition can impair the hepatic metabolic functions, and malnutrition alone can result in severe fatty liver[33].

**NUTRITIONAL STATUS ASSESSMENT**

According to the expert statements and practical guidance of the European Society for Clinical Nutrition and Metabolism for the nutritional management of individuals with SARS-CoV-2 infection, COVID-19 patients at risk of poor outcomes and high mortality, namely, the elderly and individuals with multiple comorbidities, should be assessed for malnutrition using the Malnutrition Universal Screening Tool (MUST) criteria; for hospitalized patients, the Nutrition Risk Screening 2002 (NRS-2002) criteria should be used[34]. Identification of the risk and presence of malnutrition should be conducted early in the overall assessment of all patients with COVID-19 using criteria such as MUST or NRS-2002. Ganatra *et al*[35] investigated and analyzed the nutritional risk and dietary intake of patients with COVID-19 and provided data supporting nutritional intervention using the NRS-2002 criteria. The Subjective Global Assessment criteria, the MNA criteria for geriatric patients, and the Nutrition Risk in Critically ill (NUTRIC) criteria for ICU patients have been used to further assess patients with COVID-19 and are accepted in clinical practice[36,37]. Zhang *et al*[38] reported that the modified NUTRIC score could be applied to nutritional risk evaluation and prognosis indication in critically ill patients with COVID-19[39].Recently, the GLIM criteria for malnutrition diagnosis endorsed by clinical nutrition societies worldwide have been used to assess the nutritional status of patients with COVID-19[30,31].

**NUTRITION THERAPY FOR COVID-19-RELATED LIVER DYSFUNCTION**

Currently, the fight against the COVID-19 epidemic is entering a decisive stage[38]. Evidence-based and logical nutrition interventions can effectively improve the nutritional status and enhance the immunity, and they are essential for preventing and managing viral infections[40]. Patients with mild clinical manifestations or recovered patients who have returned home should rest in bed, carefully choose foods and recipes, maintain an adequate supply of energy and nutrients (including drinking water), improve their immune status, and speed up their recovery process. Severe, critically ill patients with COVID-19 often have loss of appetite and insufficient diet, which worsens their already weak immune system. For these patients, subsequent nutritional support should be adopted, and specific nutritional treatment plans should be formulated according to the general condition of the patient’s body, fluid intake, liver and kidney functions, and glucose and lipid metabolism[41]. Ten expert recommendations for medical nutritional therapy for patients with COVID-19 have been proposed by the Chinese Society for Parenteral and Enteral Nutrition to further promote patient recovery, improve their treatment effects, and reduce the mortality rate[42]. The main nutritional therapy recommendation is a five-step method, including diet and nutrition education, oral nutritional supplements, tube feeding, supplemental parenteral nutrition, and total parenteral nutrition[42].

Numerous studies have found that nutrition therapy measures for patients with COVID-19 mainly include natural dietary supplements, vitamins, minerals, trace elements, and probiotics. A schematic summarizing the nutritional interventions for COVID-19-related liver dysfunction and their possible mechanisms is shown in Figure 2.

***Natural dietary supplements***

Rizzo *et al*[43] reviewed the properties of some vegetal products and their derivatives, including Lupin, salvia, garlic, and extra-virgin olive oil (EVOO), and they found that intake of these products or their extracts might prevent SARS-CoV-2 infection or improve the patients’ nutritional status. Lupin, salvia, garlic, and EVOO have anti-oxidant, anti-inflammatory, or antiviral properties and can recover the expression of ACE2 on the cell membrane, otherwise suppressed by SARS-CoV-2 binding and entry into the cytoplasm. Sikander *et al*[6] provided information and summarized the effects of natural bioactive antiviral, immunomodulatory, and hepatoprotective nutraceuticals (*Silybum marianum*, *Solanum nigrum*, *Cichorium intybus*, *Allium sativum*, *Glycyrrhiza glabra*, *Phyllanthus amarus*, *Withania somnifera*, *Curcuma longa*, and other hepatoprotective agents) that might be explored in managing COVID-19-induced liver dysfunction. Additionally, omega-3 long-chain polyunsaturated fatty acids (omega-3 LC-PUFAs) might also have effects on different stages of viral infection, including virus entry and replication, and help improve the inflammatory balance. An optimized omega-3 PUFA status, considering both the omega-3 precursor alpha-linolenic acid and long-chain derivatives, such as eicosapentaenoic acid and docosahexaenoic acid, might be helpful in preventing infectious diseases, including COVID-19[44].

***Vitamins***

Accumulating data have demonstrated that vitamin deficiency could be a risk factor for SARS-CoV-2 infection and it affects the COVID-19 susceptibility and prognosis[45]. For instance, vitamin A deficiency increases the severity of the disease, and appropriately timed intake during recovery reduces the death risk and speeds up the recovery. Studying interactions of vitamin A metabolism with SARS-CoV-2 infection may thus provide improved COVID-19 treatment[46]. Vitamin D deficiency may decrease the ability of the immune system to defend against COVID-19 and cause progression to severe disease[47]. Vitamin K deficiency may be a potentially modifiable risk factor for severe COVID-19; the mechanism is pneumonia-induced extrahepatic vitamin K consumption, resulting in accelerated elastic fiber damage and thrombosis[48]. Vitamins A, B, C, D, and E have been shown to be potentially beneficial in fighting against COVID-19 by exerting antioxidant and immunomodulatory effects, increasing natural barriers, and causing local paracrine signaling[49]. Additionally, vitamins can serve as epigenetic modifiers to enhance the immunity and reduce the inflammatory response in patients with COVID-19 and noncommunicable diseases. Combined vitamin therapy can improve the health in a more personalized manner or help in the prevention of infectious diseases in patients at risk for COVID-19[50]. Molecular simulations also suggest that vitamins, steroids, and retinoids may serve as ligands in the free fatty acid pocket of the SARS-CoV-2 spike protein and may thus provide a promising strategy for prophylaxis or therapeutics[51]. Supplements with vitamins A, B, C, D, E, and K may represent a cheap and safe approach and can be used as adjuvant therapy together with antiviral medicines in managing COVID-19[45,52]. However, caution must be exercised when recommending vitamin supplementation during the COVID-19 pandemic because the effects of hypervitaminosis can be serious, especially of fat-soluble vitamins A, D, and E[49]. More robust data from randomized controlled trials are needed in the near future.

***Minerals and trace elements***

Zinc (Zn) supplementation may inhibit SARS-CoV-2 virus replication, increase mucociliary clearance, and stimulate and activate the natural antiviral response of the immune system in patients with COVID-19[52]. Derwand *et al*[53] have also reported that the application of the combination therapy of Zn, low-dose hydroxychloroquine, and azithromycin to COVID-19 outpatients as early as possible after symptom onset resulted in significantly fewer hospitalizations and mortality rates.

Selenium (Se), one of the essential trace elements in the human body, has antioxidant and immunity-boosting effects that may induce a strong antiviral effect[54]. Recently, it was reported that the Se status was positively correlated with the survival rate of COVID-19 patients according to an exploratory study on the Se status in healthy individuals and patients with COVID-19 in the southern part of India[55]. Se has long been considered to help fight different viruses, such as herpes simplex virus type 1, influenza virus, Coxsackie virus, hepatitis C virus, and human immunodeficiency virus; the potential application of nano-Se may play an important role in combating COVID-19 in the future[54]. Nutrition interventions that ensure an adequate status of Zn, Se, and vitamin D could protect against infection with the novel coronavirus SARS-CoV-2 and retard the course of COVID-19. Meanwhile, the initiation of adequate supplementation of Se in high-risk population immediately after the time of suspected SARS-CoV-2 infection is recommended[56].

Magnesium (Mg) is important for the activation of vitamin D and plays a protective role against oxidative stress. Mg deficiency increases the endothelial cell susceptibility to oxidative stress, induces endothelial dysfunction, decreases fibrinolysis, and increases coagulation. Mg-deficiency in animals and humans may lead to suppressed immune responses. However, upon supplementation with Mg, a partial or nearly full reversal of immunodeficiency occurs. Since Mg and vitamin D are important for immune function and cellular resilience, deficiency of either of the two micronutrients may contribute to cytokine storms in COVID-19 infection[57]. Furthermore, a low Mg status may induce the transition from mild to critical clinical manifestations of COVID-19[58]. Additionally, a recent review summarized the effect of Mg supplementation on various types of disorders and diseases, providing a reference supporting the possibility of Mg supplementation for supportive therapy of COVID-19 patients[59]. Additional epidemiological, basic, and clinical research on the potential role of Mg deficiency in COVID-19 is needed.

Copper (Cu) is an important micronutrient for both pathogens and hosts during viral infection. It has the capability of contact killing of several viruses, including SARS-CoV-2[60]. Enrichment of plasma Cu levels was hypothesized to boost both innate and adaptive immunity; Cu may have preventive and therapeutic effects against COVID-19[60]. A better understanding of Cu signaling, safety, assessment and interpretation methods, administration route, and dosage could open up new perspectives regarding the administration of therapeutic Cu to critically ill patients with COVID-19. Andreou *et al*[61] found that the combined use of Cu, colchicine, N-acetylcysteine, and nitric oxide (NO) with candidate antiviral agents, such as remdesivir or EIDD-2801, might be a potential treatment scheme for COVID-19. Physicians should consider Cu insufficiency in critically ill patients with COVID-19 and pay attention to Cu toxicity and estimate the adverse responses according to the Cu dose, and severity of Cu limitation, as well as the duration of Cu imbalance[62].

***Probiotics***

Beneficial live microbes in humans and animals are known as probiotics, and the chemical compounds that increase the probiotic growth rate are termed prebiotics[63]. SARS-CoV-2 infection is closely related to immune dysfunction and gut microbiota alterations. Delineating the mechanisms of probiotics, prebiotics, and a diet that promotes immunity and protects against SARS-CoV-2 presents possibilities of identifying microbial therapies to prevent and treat COVID-19[64]. Probiotics can exert beneficial effects by manipulating the gut microbiome, suppressing the gut opportunistic pathogens, decreasing the translocation of opportunistic organisms in the gut, activating the mucosal immunity, and modulating the innate and adaptive immune responses. Probiotics may be used as potential candidates to treat moderate and severe COVID-19 patients due to their benefits, including safety, ease of administration, high availability, and cost-effectiveness[65]. Emerging evidence has shown the role of gut microbiota in liver diseases through immune system cross-talk[66]. There is a lack of evidence that probiotics can directly inhibit SARS-CoV-2 infection, and probiotic therapy in COVID-19-related liver dysfunction is also not very effective. However, probiotics may be potentially helpful in the treatment of patients with severe COVID-19 and liver dysfunction[67].

**CONCLUSION**

Patients with COVID-19 usually have respiratory symptoms, but liver dysfunction is not an uncommon presentation and can lead to a delay in diagnosis and management[68]. Nutrition and immune statuses are two critical aspects of the successful fight against COVID-19[55]. Prevention, diagnosis, and treatment of malnutrition should be routinely recommended in the management of patients with COVID-19, especially in those with liver dysfunction[34,69]. Nutritional therapy is a basic treatment and one of the core contents of comprehensive treatment measures for patients with COVID-19. Evidence-based effective nutritional therapy should be based on reasonable and indexed nutritional evaluation[70].

Studies have shown that nutrition therapy measures, including natural dietary supplements, vitamins, minerals, trace elements, and probiotics, might have potential hepatoprotective effects against COVID-19-related liver dysfunction *via* their antioxidant, antiviral, anti-inflammatory, and positive immunomodulatory effects. Combination therapy strategies and personalized nutritional and behavioral approaches can be developed in the COVID-19 era[52,71]. Additionally, the risk of excessive intake of some nutrients due to the popularity of dietary supplements exists, and dietitians’ use of foods with protective effects against diseases has increased during the pandemic. Hence, consumers, patients, and nutritionists should be educated on the rational use of dietary supplements and health-protecting behaviors that can protect against COVID-19 for acute treatment, recovery, and prevention of chronic condition[72,73]. Moreover, additional tools and training are needed to optimize remote nutritional consultations, except for telemedicine, which have good prospects for dietary consultation[74]. Currently, many patients with COVID-19 have liver dysfunction, but nutritional studies related to this topic are not adequate. As nutritionists, it is our responsibility and obligation to facilitate further research in this area.

**ACKNOWLEDGEMENTS**

We thank Dr. Xu-Xia Li and other colleagues, the reviewers, and the editors for improving our paper.

**REFERENCES**

1 **Abdulrab S**, Al-Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. *Med Hypotheses* 2020; **143**: 109897 [PMID: 32505909 DOI: 10.1016/j.mehy.2020.109897]

2 **Mahase E**. Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. *BMJ* 2020; **368**: m1036 [PMID: 32165426 DOI: 10.1136/bmj.m1036]

3 **World Health Organization**. Weekly epidemiological update on COVID-19 - 6 January 2022. [cited 6 January 2022]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-january-2022

4 **Yasutake K**, Kohjima M, Nakashima M, Kotoh K, Nakamuta M, Enjoji M. Nutrition therapy for liver diseases based on the status of nutritional intake. *Gastroenterol Res Pract* 2012; **2012**: 859697 [PMID: 23197979 DOI: 10.1155/2012/859697]

5 **Cichoż-Lach H**, Michalak A. Liver injury in the era of COVID-19. *World J Gastroenterol* 2021; **27**: 377-390 [PMID: 33584070 DOI: 10.3748/wjg.v27.i5.377]

6 **Sikander M**, Malik S, Rodriguez A, Yallapu MM, Narula AS, Satapathy SK, Dhevan V, Chauhan SC, Jaggi M. Role of Nutraceuticals in COVID-19 Mediated Liver Dysfunction. *Molecules* 2020; **25** [PMID: 33322162 DOI: 10.3390/molecules25245905]

7 **Loganathan S**, Kuppusamy M, Wankhar W, Gurugubelli KR, Mahadevappa VH, Lepcha L, Choudhary AK. Angiotensin-converting enzyme 2 (ACE2): COVID 19 gate way to multiple organ failure syndromes. *Respir Physiol Neurobiol* 2021; **283**: 103548 [PMID: 32956843 DOI: 10.1016/j.resp.2020.103548]

8 **Hoffmann M**, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020; **181**: 271-280.e8 [PMID: 32142651 DOI: 10.1016/j.cell.2020.02.052]

9 **Merola E**, Pravadelli C, de Pretis G. Prevalence of liver injury in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. *Acta Gastroenterol Belg* 2020; **83**: 454-460 [PMID: 33094594]

10 **Phipps MM**, Barraza LH, LaSota ED, Sobieszczyk ME, Pereira MR, Zheng EX, Fox AN, Zucker J, Verna EC. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. *Hepatology* 2020; **72**: 807-817 [PMID: 32473607 DOI: 10.1002/hep.31404]

11 **Jothimani D**, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. *J Hepatol* 2020; **73**: 1231-1240 [PMID: 32553666 DOI: 10.1016/j.jhep.2020.06.006]

12 **Kaushik A**, Wani SN, Baba MA, Agarwal AK. Prevalence of Abnormal Liver Function Tests in COVID-19 Patients at a Tertiary Care Centre. *J Assoc Physicians India* 2020; **68**: 73-75 [PMID: 32738845]

13 **Hanje AJ**, Fortune B, Song M, Hill D, McClain C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. *Nutr Clin Pract* 2006; **21**: 255-272 [PMID: 16772543 DOI: 10.1177/0115426506021003255]

14 **Muthuvattur Pallath M**, Ahirwar AK, Chandra Tripathi S, Asia P, Sakarde A, Gopal N. COVID-19 and nutritional deficiency: a review of existing knowledge. *Horm Mol Biol Clin Investig* 2021; **42**: 77-85 [PMID: 33544528 DOI: 10.1515/hmbci-2020-0074]

15 **Briguglio M**, Pregliasco FE, Lombardi G, Perazzo P, Banfi G. The Malnutritional Status of the Host as a Virulence Factor for New Coronavirus SARS-CoV-2. *Front Med (Lausanne)* 2020; **7**: 146 [PMID: 32391367 DOI: 10.3389/fmed.2020.00146]

16 **Cai** CJ. Nutritional therapy in patients with liver dysfunction. *Chin J Pract Surg* 2019; **39**: 79-84 [DOI: 10.19538/j.cjps.issn1005-2208.2019.01.14]

17 **Fedele D**, De Francesco A, Riso S, Collo A. Obesity, malnutrition, and trace element deficiency in the coronavirus disease (COVID-19) pandemic: An overview. *Nutrition* 2021; **81**: 111016 [PMID: 33059127 DOI: 10.1016/j.nut.2020.111016]

18 **Wu Y**, Li H, Guo X, Yoshida EM, Mendez-Sanchez N, Levi Sandri GB, Teschke R, Romeiro FG, Shukla A, Qi X. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. *Hepatol Int* 2020; **14**: 621-637 [PMID: 32710250 DOI: 10.1007/s12072-020-10074-6]

19 **Ye L**, Chen B, Wang Y, Yang Y, Zeng J, Deng G, Deng Y, Zeng F. Prognostic value of liver biochemical parameters for COVID-19 mortality. *Ann Hepatol* 2021; **21**: 100279 [PMID: 33157267 DOI: 10.1016/j.aohep.2020.10.007]

20 **Lin L**, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, Gu Z, Gao L, Shi H, Mai L, Liu Y, Lin X, Lai R, Yan Z, Li X, Shan H. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. *Gut* 2020; **69**: 997-1001 [PMID: 32241899 DOI: 10.1136/gutjnl-2020-321013]

21 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

22 **Hajifathalian K**, Krisko T, Mehta A, Kumar S, Schwartz R, Fortune B, Sharaiha RZ; WCM-GI research group∗. Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications. *Gastroenterology* 2020; **159**: 1137-1140.e2 [PMID: 32389667 DOI: 10.1053/j.gastro.2020.05.010]

23 **Chen T**, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020; **368**: m1091 [PMID: 32217556 DOI: 10.1136/bmj.m1091]

24 **Huang C**, Li Q, Xu W, Chen L. Molecular and cellular mechanisms of liver dysfunction in COVID-19. *Discov Med* 2020; **30**: 107-112 [PMID: 33382966]

25 **Lizardo-Thiebaud MJ**, Cervantes-Alvarez E, Limon-de la Rosa N, Tejeda-Dominguez F, Palacios-Jimenez M, Méndez-Guerrero O, Delaye-Martinez M, Rodriguez-Alvarez F, Romero-Morales B, Liu WH, Huang CA, Kershenobich D, Navarro-Alvarez N. Direct or Collateral Liver Damage in SARS-CoV-2-Infected Patients. *Semin Liver Dis* 2020; **40**: 321-330 [PMID: 32886936 DOI: 10.1055/s-0040-1715108]

26 **Li J**, Fan JG. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. *J Clin Transl Hepatol* 2020; **8**: 13-17 [PMID: 32274341 DOI: 10.14218/JCTH.2020.00019]

27 **Zhong P**, Xu J, Yang D, Shen Y, Wang L, Feng Y, Du C, Song Y, Wu C, Hu X, Sun Y. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. *Signal Transduct Target Ther* 2020; **5**: 256 [PMID: 33139693 DOI: 10.1038/s41392-020-00373-7]

28 **Yang RX**, Zheng RD, Fan JG. Etiology and management of liver injury in patients with COVID-19. *World J Gastroenterol* 2020; **26**: 4753-4762 [PMID: 32921955 DOI: 10.3748/wjg.v26.i32.4753]

29 **Chapple LS**, Fetterplace K, Asrani V, Burrell A, Cheng AC, Collins P, Doola R, Ferrie S, Marshall AP, Ridley EJ. Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand. *Aust Crit Care* 2020; **33**: 399-406 [PMID: 32682671 DOI: 10.1016/j.aucc.2020.06.002]

30 **Rouget A**, Vardon-Bounes F, Lorber P, Vavasseur A, Marion O, Marcheix B, Lairez O, Balardy L, Fourcade O, Conil JM, Minville V. Prevalence of malnutrition in coronavirus disease 19: the NUTRICOV study. *Br J Nutr* 2021; **126**: 1296-1303 [PMID: 33342449 DOI: 10.1017/S0007114520005127]

31 **Bedock D**, Bel Lassen P, Mathian A, Moreau P, Couffignal J, Ciangura C, Poitou-Bernert C, Jeannin AC, Mosbah H, Fadlallah J, Amoura Z, Oppert JM, Faucher P. Prevalence and severity of malnutrition in hospitalized COVID-19 patients. *Clin Nutr ESPEN* 2020; **40**: 214-219 [PMID: 33183539 DOI: 10.1016/j.clnesp.2020.09.018]

32 **Li T**, Zhang Y, Gong C, Wang J, Liu B, Shi L, Duan J. Prevalence of malnutrition and analysis of related factors in elderly patients with COVID-19 in Wuhan, China. *Eur J Clin Nutr* 2020; **74**: 871-875 [PMID: 32322046 DOI: 10.1038/s41430-020-0642-3]

33 **Bischoff SC**, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Plauth M. ESPEN practical guideline: Clinical nutrition in liver disease. *Clin Nutr* 2020; **39**: 3533-3562 [PMID: 33213977 DOI: 10.1016/j.clnu.2020.09.001]

34 **Barazzoni R**, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D, Pirlich M, Singer P; endorsed by the ESPEN Council. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. *Clin Nutr* 2020; **39**: 1631-1638 [PMID: 32305181 DOI: 10.1016/j.clnu.2020.03.022]

35 **Ganatra S**, Hammond SP, Nohria A. The Novel Coronavirus Disease (COVID-19) Threat for Patients With Cardiovascular Disease and Cancer. *JACC CardioOncol* 2020; **2**: 350-355 [PMID: 32292919 DOI: 10.1016/j.jaccao.2020.03.001]

36 **Martins PM**, Gomes TLN, Franco EP, Vieira LL, Pimentel GD. High neutrophil-to-lymphocyte ratio at intensive care unit admission is associated with nutrition risk in patients with COVID-19. *JPEN J Parenter Enteral Nutr* 2021 [PMID: 34961953 DOI: 10.1002/jpen.2318]

37 **Ali AM**, Kunugi H. Approaches to Nutritional Screening in Patients with Coronavirus Disease 2019 (COVID-19). *Int J Environ Res Public Health* 2021; **18** [PMID: 33803339 DOI: 10.3390/ijerph18052772]

38 **Zhang P**, He Z, Yu G, Peng D, Feng Y, Ling J, Wang Y, Li S, Bian Y. The modified NUTRIC score can be used for nutritional risk assessment as well as prognosis prediction in critically ill COVID-19 patients. *Clin Nutr* 2021; **40**: 534-541 [PMID: 32527576 DOI: 10.1016/j.clnu.2020.05.051]

39 **Nutrition Management in Critically Ill Project Team,** Chinese Nutrition Society for Clinical Nutrition. Recommendations for nutrition therapy in critically ill COVID-19 patients. *Chin J Clin Med* 2020; **27**: 167-174 [DOI: 10.12025/j.issn.1008-6358.2020. 20200436]

40 **Jayawardena R**, Sooriyaarachchi P, Chourdakis M, Jeewandara C, Ranasinghe P. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review. *Diabetes Metab Syndr* 2020; **14**: 367-382 [PMID: 32334392 DOI: 10.1016/j.dsx.2020.04.015]

41 **Law S**, Leung AW, Xu C. Severe acute respiratory syndrome (SARS) and coronavirus disease-2019 (COVID-19): From causes to preventions in Hong Kong. *Int J Infect Dis* 2020; **94**: 156-163 [PMID: 32251790 DOI: 10.1016/j.ijid.2020.03.059]

42 **Chinese Society for Parenteral and Enteral Nutrition**. Expert advice of medical nutritional treatment for novel coronavirus-caused pneumonia patients. *Chin Arch Gen Surg* 2020; **14**: 1 [DOI: 10.3877/cma.j.issn.1674-0793.2020.01.001]

43 **Rizzo A**, Sciorsci RL, Magrone T, Jirillo E. Exploitation of Some Natural Products for the Prevention and/or Nutritional Treatment of SARS-CoV2 Infection. *Endocr Metab Immune Disord Drug Targets* 2021; **21**: 1171-1182 [PMID: 32875990 DOI: 10.2174/1871530320999200831231029]

44 **Weill P**, Plissonneau C, Legrand P, Rioux V, Thibault R. May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients? *Biochimie* 2020; **179**: 275-280 [PMID: 32920170 DOI: 10.1016/j.biochi.2020.09.003]

45 **Allegra A**, Tonacci A, Pioggia G, Musolino C, Gangemi S. Vitamin deficiency as risk factor for SARS-CoV-2 infection: correlation with susceptibility and prognosis. *Eur Rev Med Pharmacol Sci* 2020; **24**: 9721-9738 [PMID: 33015818 DOI: 10.26355/eurrev\_202009\_23064]

46 **Stephensen CB**, Lietz G. Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2. *Br J Nutr* 2021; **126**: 1663-1672 [PMID: 33468263 DOI: 10.1017/S0007114521000246]

47 **Im JH**, Je YS, Baek J, Chung MH, Kwon HY, Lee JS. Nutritional status of patients with COVID-19. *Int J Infect Dis* 2020; **100**: 390-393 [PMID: 32795605 DOI: 10.1016/j.ijid.2020.08.018]

48 **Dofferhoff ASM**, Piscaer I, Schurgers LJ, Visser MPJ, van den Ouweland JMW, de Jong PA, Gosens R, Hackeng TM, van Daal H, Lux P, Maassen C, Karssemeijer EGA, Vermeer C, Wouters EFM, Kistemaker LEM, Walk J, Janssen R. Reduced Vitamin K Status as a Potentially Modifiable Risk Factor of Severe Coronavirus Disease 2019. *Clin Infect Dis* 2021; **73**: e4039-e4046 [PMID: 32852539 DOI: 10.1093/cid/ciaa1258]

49 **Jovic TH**, Ali SR, Ibrahim N, Jessop ZM, Tarassoli SP, Dobbs TD, Holford P, Thornton CA, Whitaker IS. Could Vitamins Help in the Fight Against COVID-19? *Nutrients* 2020; **12** [PMID: 32842513 DOI: 10.3390/nu12092550]

50 **Singh V**. Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease? *Curr Nutr Rep* 2020; **9**: 202-209 [PMID: 32661859 DOI: 10.1007/s13668-020-00330-4]

51 **Shoemark DK**, Colenso CK, Toelzer C, Gupta K, Sessions RB, Davidson AD, Berger I, Schaffitzel C, Spencer J, Mulholland AJ. Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein\*. *Angew Chem Int Ed Engl* 2021; **60**: 7098-7110 [PMID: 33469977 DOI: 10.1002/anie.202015639]

52 **Islam MT**, Quispe C, Martorell M, Docea AO, Salehi B, Calina D, Reiner Ž, Sharifi-Rad J. Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19. *Int J Vitam Nutr Res* 2022; **92**: 49-66 [PMID: 33435749 DOI: 10.1024/0300-9831/a000694]

53 **Derwand R**, Scholz M, Zelenko V. COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. *Int J Antimicrob Agents* 2020; **56**: 106214 [PMID: 33122096 DOI: 10.1016/j.ijantimicag.2020.106214]

54 **He L**, Zhao J, Wang L, Liu Q, Fan Y, Li B, Yu YL, Chen C, Li YF. Using nano-selenium to combat Coronavirus Disease 2019 (COVID-19)? *Nano Today* 2021; **36**: 101037 [PMID: 33250930 DOI: 10.1016/j.nantod.2020.101037]

55 **Majeed M**, Nagabhushanam K, Gowda S, Mundkur L. An exploratory study of selenium status in healthy individuals and in patients with COVID-19 in a south Indian population: The case for adequate selenium status. *Nutrition* 2021; **82**: 111053 [PMID: 33321395 DOI: 10.1016/j.nut.2020.111053]

56 **Alexander J**, Tinkov A, Strand TA, Alehagen U, Skalny A, Aaseth J. Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19. *Nutrients* 2020; **12** [PMID: 32784601 DOI: 10.3390/nu12082358]

57 **DiNicolantonio JJ**, O'Keefe JH. Magnesium and Vitamin D Deficiency as a Potential Cause of Immune Dysfunction, Cytokine Storm and Disseminated Intravascular Coagulation in covid-19 patients. *Mo Med* 2021; **118**: 68-73 [PMID: 33551489]

58 **Iotti S**, Wolf F, Mazur A, Maier JA. The COVID-19 pandemic: is there a role for magnesium? Hypotheses and perspectives. *Magnes Res* 2020; **33**: 21-27 [PMID: 32554340 DOI: 10.1684/mrh.2020.0465]

59 **Tang CF**, Ding H, Jiao RQ, Wu XX, Kong LD. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. *Eur J Pharmacol* 2020; **886**: 173546 [PMID: 32931782 DOI: 10.1016/j.ejphar.2020.173546]

60 **Raha S**, Mallick R, Basak S, Duttaroy AK. Is copper beneficial for COVID-19 patients? *Med Hypotheses* 2020; **142**: 109814 [PMID: 32388476 DOI: 10.1016/j.mehy.2020.109814]

61 **Andreou A**, Trantza S, Filippou D, Sipsas N, Tsiodras S. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. *In Vivo* 2020; **34**: 1567-1588 [PMID: 32503814 DOI: 10.21873/invivo.11946]

62 **Fooladi S**, Matin S, Mahmoodpoor A. Copper as a potential adjunct therapy for critically ill COVID-19 patients. *Clin Nutr ESPEN* 2020; **40**: 90-91 [PMID: 33183578 DOI: 10.1016/j.clnesp.2020.09.022]

63 **Khaled JMA**. Probiotics, prebiotics, and COVID-19 infection: A review article. *Saudi J Biol Sci* 2021; **28**: 865-869 [PMID: 33424377 DOI: 10.1016/j.sjbs.2020.11.025]

64 **Hu J**, Zhang L, Lin W, Tang W, Chan FKL, Ng SC. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. *Trends Food Sci Technol* 2021; **108**: 187-196 [PMID: 33519087 DOI: 10.1016/j.tifs.2020.12.009]

65 **Angurana SK**, Bansal A. Probiotics and Coronavirus disease 2019: think about the link. *Br J Nutr* 2021; **126**: 1564-1570 [PMID: 32921328 DOI: 10.1017/S000711452000361X]

66 **Scarpellini E**, Fagoonee S, Rinninella E, Rasetti C, Aquila I, Larussa T, Ricci P, Luzza F, Abenavoli L. Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. *J Clin Med* 2020; **9** [PMID: 32756323 DOI: 10.3390/jcm9082488]

67 **Aguila EJT**, Lontok MADC, Aguila EJT. Letter: role of probiotics in the COVID-19 pandemic. *Aliment Pharmacol Ther* 2020; **52**: 931-932 [PMID: 32852829 DOI: 10.1111/apt.15898]

68 **Kamani L**. What gastroenterologists should know during COVID-19 Pandemic!. *Pak J Med Sci* 2020; **36**: S124-S125 [PMID: 32582330 DOI: 10.12669/pjms.36.COVID19-S4.2651]

69 **Cervantes-Pérez E**, Cervantes-Guevara G, Martínez-Soto Holguín MC, Cervantes-Pérez LA, Cervantes-Pérez G, Cervantes-Cardona GA, González-Ojeda A, Fuentes-Orozco C, Ramírez-Ochoa S. Medical Nutrition Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection in a Non-critical Care Setting: Knowledge in Progress. *Curr Nutr Rep* 2020; **9**: 309-315 [PMID: 33125628 DOI: 10.1007/s13668-020-00337-x]

70 **Yu KY**, Shi HP. [Explanation of expert recommendations on medical nutrition for patients with novel coronavirus pneumonia]. *Zhonghua Yi Xue Za Zhi* 2020; **100**: 724-728 [PMID: 32192285 DOI: 10.3760/cma.j.cn112137-20200205-00196]

71 **Formisano E**, Di Maio P, Ivaldi C, Sferrazzo E, Arieta L, Bongiovanni S, Panizzi L, Valentino E, Pasta A, Giudice M, Demontis S. Nutritional therapy for patients with coronavirus disease 2019 (COVID-19): Practical protocol from a single center highly affected by an outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. *Nutrition* 2021; **82**: 111048 [PMID: 33277149 DOI: 10.1016/j.nut.2020.111048]

72 **Hamulka J**, Jeruszka-Bielak M, Górnicka M, Drywień ME, Zielinska-Pukos MA. Dietary Supplements during COVID-19 Outbreak. Results of Google Trends Analysis Supported by PLifeCOVID-19 Online Studies. *Nutrients* 2020; **13** [PMID: 33375422 DOI: 10.3390/nu13010054]

73 **Kamarli Altun H**, Karacil Ermumcu MS, Seremet Kurklu N. Evaluation of dietary supplement, functional food and herbal medicine use by dietitians during the COVID-19 pandemic. *Public Health Nutr* 2021; **24**: 861-869 [PMID: 33357253 DOI: 10.1017/S1368980020005297]

74 **Kaufman-Shriqui V**, Sherf-Dagan S, Boaz M, Birk R. Virtual nutrition consultation: what can we learn from the COVID-19 pandemic? *Public Health Nutr* 2021; **24**: 1166-1173 [PMID: 33436134 DOI: 10.1017/S1368980021000148]

**Footnotes**

**Conflict-of-interest statement:** There areno conflict of interest related to this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 12, 2021

**First decision:** April 17, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Khan MKA, India **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:**

**Figure Legends**



**Figure 1 Mechanisms of coronavirus disease 2019-related liver dysfunction.** COVID-19: Coronavirus disease 2019.



**Figure 2 Scheme showing the effects of nutritional interventions against coronavirus disease 2019-related liver dysfunction and their possible mechanisms.** SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; COVID-19: Coronavirus disease 2019.